Abstracts

Effect of Raltegravir Intensification in the Cytokine Profile of Treated HIV+ Individuals

Background: Inflammatory markers are increased in untreated HIV infected individuals and, as immune activation, are not normalized by combination antiretroviral therapy (cART). Long term (48 weeks) intensification of cART with Raltegravir reduced CD8 T-cell activation in the Discorral and IntegRal studies. Therefore, we have evaluated the effect of Raltegravir intensification in several soluble plasma markers…

Pathogenesis of JC Virus Reactivation During Natalizumab Treatment

Background: Progressive multifocal leukoencephalopathy (PML), caused by JC virus (JCV), is an opportunistic infection in immunocompromised hosts and its pathogenesis remains elusive. Recently, PML affects multiple sclerosis (MS) patients treated with natalizumab, a monoclonal antibody against alpha-4 integrins which prevents entry of inflammatory cells in the central nervous system. We sought to uncover the site…

Impaired T. pallidum Opsonic Antibody Function in HIV-Infected Patients With Neurosyphilis

Background: Compared to HIV-uninfected (HIV-) patients, HIV-infected (HIV+) patients may be at increased risk of neurosyphilis (NS). T. pallidum, the bacterium that causes syphilis, is cleared from sites of infection by activated macrophages that ingest and kill opsonized organisms. We hypothesized that HIV+ individuals might have a defect in opsonic antibody production or function that…

Labyrinthopeptin A1 Demonstrates Potent and Dual Anti-HSV and Anti-HIV Activity

Background: It has been shown that genital lesions and altered innate mucosal immunity caused by HSV-2 are important cofactors to increase the rate of HIV transmission and infection. Therefore, a product that inhibits HIV and HSV would have potential benefits in the prophylaxis against these sexually transmitted viruses. Lantibiotics are peptides that contain the noncanonical…

GSK1265744 Demonstrates Robust In Vitro Activity Against Various Clades of HIV-1

Background: GSK1265744 (744) is a potent integrase strand-transfer inhibitor formulated as a long acting (LA) injection; 744LA is being tested preclinically as pre-exposure prophylaxis (PrEP) in the rhesus macaque/SHIV162P3 model. To confirm the promise of 744LA as PrEP we analyzed the susceptibility of recombinant viruses containing patient-derived HIV-1 integrase from various recently acquired HIV-1 clades…

The Adjuvant Used in an ALVAC/gp120 Regimen Alters Plasmablast Homing Markers in Macaque and Humans

Background: An ALVAC-HIV/gp120 vaccine provided limited but significant protection against HIV-1 acquisition (31.2%) in RV144 trial. Antibodies against the envelope were associated with reduced risk of HIV acquisition. The frequency of plasmablasts (PBs) has been shown to correlate with protection from SIV acquisition in macaques. Increasing evidence indicates that chemokines and their receptors have a…